drugset
drugset / Trial / NCT03397862

A Skin Irritation Assessment of Once-Weekly Corplex™ Donepezil Transdermal Delivery System

NCT03397862 ↗

Phase 1 Completed 256 enrolled Corium, Inc.
RandomizedSequentialQuadruple-blindOther

Summary

A study to assess the skin irritation and sensitization potential of Corplex™ Donepezil Transdermal Delivery System (TDS)

Timeline

Start
2017-11-14
Primary completion
2018-03-08
Completion
2018-04-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Donepezil Small molecule 5 mg Other

Indications

skin disorder